Key result
Hepatic angiosarcoma was associated with increased urinary hyaluronidase-resistant heparan sulfate and decreased hyaluronidase-susceptible chondroitin sulfate compared to controls.
Case-Control
Urinary glycosaminoglycan patterns, specifically increased heparan sulfate and decreased chondroitin-4/6-sulfate, are altered in patients with hepatic angiosarcoma and correlate with disease progression.
May support noninvasive hepatic angiosarcoma detection; leaves open prospective validation before clinical adoption.
Glycosaminoglycans extracted from 24-hour urine specimens from patients with hepatic angiosarcoma and from normal/controls were separated as cetylpyridinium complexes into "hyaluronic acid," "chondroitin sulfate," and "heparin" fractions, then further separated and characterized by anion-exchange chromatography and hyaluronidase susceptibility. The chromatographic pattern of the urinary chondroitin sulfate fraction in patients with angiosarcoma of the liver differed from those of controls in that there was a relative increase in the total amount of uronic acid in a hyaluronidase-resistant fraction and a decrease in a fraction susceptible to hyaluronidase digestion. These changes appeared to become more pronounced with advancing disease. Chromatographic patterns and determinations of hyaluronidase susceptibility indicated that the resistant fraction was heparan sulfate and that the susceptible fraction was chondroitin-4-sulfate and/or chondroitin-6-sulfate.
No takes yet. Share an insight, caveat, or question.
Curran et al. (1977) conducted a case-control in Hepatic angiosarcoma. Hepatic angiosarcoma vs. Normal controls was evaluated on Chromatographic pattern of urinary chondroitin sulfate fraction. Hepatic angiosarcoma was associated with increased urinary hyaluronidase-resistant heparan sulfate and decreased hyaluronidase-susceptible chondroitin sulfate compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: